Mark Daniel Deboer1. 1. Division of Pediatric Endocrinology, University of Virginia.
Abstract
BACKGROUND: Cachexia is a devastating syndrome of body wasting that worsens quality of life and survival for patients suffering from diseases such as cancer, chronic kidney disease and chronic heart failure. Successful treatments have been elusive in humans, leaving a clear need for the development of new treatment compounds. Animal models of cachexia are able to recapitulate the clinical findings from human disease and have provided a much-needed means of testing the efficacy of prospective therapies. OBJECTIVE: This review focuses on animal models of cachexia caused by cancer, chronic heart failure and chronic kidney disease, including the features of these models, their implementation, and commonly-followed outcome measures. CONCLUSION: Given a dire clinical need for effective treatments of cachexia, animal models will continue a vital role in assessing the efficacy and safety of potential treatments prior to testing in humans. Also important in the future will be the use of animal models to assess the durability of effect from anti-cachexia treatments and their effect on prognosis of the underlying disease states.
BACKGROUND:Cachexia is a devastating syndrome of body wasting that worsens quality of life and survival for patients suffering from diseases such as cancer, chronic kidney disease and chronic heart failure. Successful treatments have been elusive in humans, leaving a clear need for the development of new treatment compounds. Animal models of cachexia are able to recapitulate the clinical findings from human disease and have provided a much-needed means of testing the efficacy of prospective therapies. OBJECTIVE: This review focuses on animal models of cachexia caused by cancer, chronic heart failure and chronic kidney disease, including the features of these models, their implementation, and commonly-followed outcome measures. CONCLUSION: Given a dire clinical need for effective treatments of cachexia, animal models will continue a vital role in assessing the efficacy and safety of potential treatments prior to testing in humans. Also important in the future will be the use of animal models to assess the durability of effect from anti-cachexia treatments and their effect on prognosis of the underlying disease states.
Authors: A Rashid Qureshi; Anders Alvestrand; José C Divino-Filho; Alberto Gutierrez; Olof Heimbürger; Bengt Lindholm; Jonas Bergström Journal: J Am Soc Nephrol Date: 2002-01 Impact factor: 10.121
Authors: Joe A Tran; Wanlong Jiang; Fabio C Tucci; Beth A Fleck; Jenny Wen; Yang Sai; Ajay Madan; Ta Kung Chen; Stacy Markison; Alan C Foster; Sam R Hoare; Daniel Marks; John Harman; Caroline W Chen; Melissa Arellano; Dragan Marinkovic; Haig Bozigian; John Saunders; Chen Chen Journal: J Med Chem Date: 2007-11-10 Impact factor: 7.446
Authors: W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey Journal: Am J Med Date: 1980-10 Impact factor: 4.965
Authors: Tricia J Vos; Andrei Caracoti; Jennifer L Che; Mingshi Dai; Cheryl A Farrer; Nancy E Forsyth; Stacey V Drabic; Robert A Horlick; Diana Lamppu; David L Yowe; Suresh Balani; Ping Li; Hang Zeng; Ingrid B J K Joseph; Luis E Rodriguez; Martin P Maguire; Michael A Patane; Christopher F Claiborne Journal: J Med Chem Date: 2004-03-25 Impact factor: 7.446
Authors: Yoshihiro J Akashi; Sandra Palus; Rakesh Datta; Heather Halem; John E Taylor; Christa Thoene-Reineke; Jesse Dong; Thomas Thum; Michael D Culler; Stefan D Anker; Jochen Springer Journal: Int J Cardiol Date: 2008-08-23 Impact factor: 4.164
Authors: K van Norren; D Kegler; J M Argilés; Y Luiking; M Gorselink; A Laviano; K Arts; J Faber; H Jansen; E M van der Beek; A van Helvoort Journal: Br J Cancer Date: 2009-03-10 Impact factor: 7.640
Authors: Stephanie J Melchor; Claire M Saunders; Imani Sanders; Jessica A Hatter; Kari A Byrnes; Sheryl Coutermarsh-Ott; Sarah E Ewald Journal: J Immunol Date: 2020-04-29 Impact factor: 5.422
Authors: Kevin G Burfeind; Xinxia Zhu; Peter R Levasseur; Katherine A Michaelis; Mason A Norgard; Daniel L Marks Journal: Brain Behav Immun Date: 2018-05-28 Impact factor: 7.217
Authors: Lauren R Brinster; Romelda L Omeir; Gideon S Foseh; Juliete N Macauley; Philip J Snoy; Joel J Beren; Belete Teferedegne; Keith Peden; Andrew M Lewis Journal: Comp Med Date: 2013-08 Impact factor: 0.982
Authors: Souad Mubaid; Jennifer F Ma; Amr Omer; Kholoud Ashour; Xian J Lian; Brenda J Sanchez; Samantha Robinson; Anne Cammas; Virginie Dormoy-Raclet; Sergio Di Marco; Sridar V Chittur; Scott A Tenenbaum; Imed-Eddine Gallouzi Journal: Proc Natl Acad Sci U S A Date: 2019-08-12 Impact factor: 11.205
Authors: Roberto Mota; Jessica E Rodríguez; Andrea Bonetto; Thomas M O'Connell; Scott A Asher; Traci L Parry; Pamela Lockyer; Christopher R McCudden; Marion E Couch; Monte S Willis Journal: Am J Cancer Res Date: 2017-09-01 Impact factor: 6.166
Authors: Serkan Kir; Hirotaka Komaba; Ana P Garcia; Konstantinos P Economopoulos; Wei Liu; Beate Lanske; Richard A Hodin; Bruce M Spiegelman Journal: Cell Metab Date: 2015-12-06 Impact factor: 27.287